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Abstract
Background: Multiple immune evasion strategies by which HCV establishes chronic infection have
been proposed, including manipulation of cytokine responses. Prior infection with HIV increases
the likelihood of chronic HCV infection and accelerates development of HCV-related morbidity.
Therefore, we investigated in vitro cytokine responses to HCV structural and non-structural
proteins in peripheral blood mononuclear cells (PBMC) from uninfected, HIV-infected, HCV-
infected and HIV/HCV-coinfected individuals.
Results: Intracellular flow cytometry was used to assess IL-2, IL-10, IL-12, and IFN-γ production
by freshly isolated PBMC incubated for 16 hours with recombinant HCV core, non-structural
protein 3 (NS3), and NS4 proteins. Anti-HCV cellular responses were assessed in HIV/HCV-
coinfected individuals by 3H-thymidine proliferation assay. Exposure to HCV antigens increased IL-
10 production by PBMC, especially in uninfected and HIV-monoinfected individuals. This IL-10
response was attenuated in chronic HCV infection even with HCV/HIV-coinfection. The cells
producing IL-10 in response to HCV proteins in vitro matched a PBMC subset recently shown to
constitutively produce IL-10 in vivo. This subset was found at similar frequencies in uninfected, HIV-
infected, HCV-infected and HIV/HCV-coinfected individuals before exposure to HCV proteins.
HCV-specific T cell proliferation was detectable in only one HIV/HCV-coinfected individual who
demonstrated no HCV-induced IL-10 response.
Conclusion: This pattern suggests that selective induction of IL-10 in uninfected individuals and
especially in HIV-monoinfected individuals plays a role in establishing chronic HCV infection and
conversely, that attenuation of this response, once chronic infection is established, favours
development of hepatic immunopathology.
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Background
Most viral infections induce cellular and humoral
immune responses that act in concert to limit viral spread,
clear infection and provide protective immunity against
reinfection with the same virus. However, a number of
viruses have evolved varied and sophisticated mecha-
nisms to establish persistent infection, even in immuno-
competent hosts [1-4]. Epstein-Barr virus (EBV) produces
an interleukin-10-like virokine that functionally mimics
IL-10 in downregulating cellular immune responses [4].
Hepatitis C virus (HCV) causes significant morbidity and
mortality. Approximately 80% of HCV-exposed individu-
als develop life-long infection and in many cases, progres-
sive liver disease [5]. Immune escape through mutations
introduced by the error prone HCV RNA-dependent RNA
polymerase is believed to play a major role in the estab-
lishment of persistent HCV infection as strong, broadly
directed cellular responses during acute infection are asso-
ciated with HCV clearance, while narrow, qualitatively
impaired anti-HCV responses occur in chronic infection
[6-12]. Clearance of HCV after interferon-alpha (IFN-α)
and ribavirin therapy is also associated with greater
breadth and amplitude of anti-HCV cellular immunity
[13,14]. These associations suggest that development of
appropriate adaptive immune responses relates closely to
HCV clearance.
The relatively small RNA genome of HCV encodes few
proteins, all of which are involved in some way with vir-
ion structure or virus replication. Hence, any immunosup-
pressive activity must reflect secondary functions of the
structural or non-structural HCV proteins. Core, non-
structural protein 3 (NS3), NS4 and NS5 have been inves-
tigated for a variety of secondary functions. The 20 kDa
HCV core protein is associated with cellular transforma-
tion in vitro and modulation of cytokine signalling and
cellular immune responses [15-17]. The NS3 serine pro-
tease downregulates immunoproteosome activity in vitro
and may impair immune recognition [18]. NS4 is com-
prised of NS4A and NS4B, two proteins involved in viral
replication. NS4A acts as a cofactor in forming the active
protease NS4A/NS3 that participates in polyprotein
processing during HCV replication [19], while NS4B is
essential for replication and seems to affect the intracellu-
lar membranous web where viral replication occurs [20].
NS5A inhibits antiviral PKR activity through its interferon
sensitivity determining region (ISDR) [21]. Thus, multiple
HCV proteins appear to have evolved secondary functions
affecting both innate and adaptive immune responses.
Viral infection generally triggers production of pro-
inflammatory cytokines, but as described above, viruses
have evolved gene products that promote persistent infec-
tion by tipping the cytokine balance towards immuno-
suppression. The setting in which viral exposure initially
occurs is also relevant, therefore, we compared induction
of cytokines by HCV proteins in PBMC from uninfected,
HCV-infected, HIV-infected and HIV/HCV-coinfected
individuals. Production of the immunosuppressive
cytokine IL-10 was selectively triggered by HCV proteins,
and the response was greater in HIV-monoinfected and
uninfected individuals than in those exposed to HCV.
This pattern suggests that selective induction of IL-10 in
uninfected individuals and especially in HIV-monoin-
fected individuals plays a role in establishing chronic
HCV infection and conversely, that attenuation of this
response, once chronic infection is established, favours
development of hepatic immunopathology.
Results
Study participants
Eight healthy volunteers from St. John's NL, Canada pro-
vided blood samples for the study. Twenty-four HIV-
infected, 10 HIV/HCV-coinfected, and 3 HCV-infected
individuals were also recruited, and Table 1 describes the
baseline characteristics of the infected groups. The age and
sex of participants was similar across groups. Most indi-
viduals exposed to HCV developed chronic infection,
although 2 of the HIV/HCV-coinfected individuals had
cleared the virus and were anti-HCV antibody positive but
HCV RNA negative. HIV related clinical parameters were
similar between groups, although there was a statistically
nonsignificant trend toward higher CD4+ T cell counts in
the coinfected group. Most HIV-infected individuals were
on antiviral therapy and had achieved viral suppression at
the time of participation. Only one of the HIV/HCV-coin-
fected individuals had been treated (unsuccessfully) with
HCV antiviral therapy, and the remainder of HCV exposed
patients were untreated.
Exposure to HCV proteins induces IL-10 production in 
PBMC
To investigate the cytokine response of PBMC from differ-
ent groups of individuals to HCV proteins, we incubated
PBMC from uninfected, HIV-infected, HCV-infected and
HIV/HCV-coinfected individuals for 16 hours with HCV
core, NS3 and NS4 proteins. Production of IL-2, IL-12,
IFN-γ and IL-10 was then assessed by intracellular flow
cytometry. Positive controls for each of these four
cytokines demonstrated the efficacy of the antibodies
(Figure 1). In no case did any of the HCV antigens, indi-
vidually or together, induce IL-2, IL-10, IFN-γ, or IL-12
production (Figure 2). However, IL-10+CD3-CD19-CD14-
CD36+CD61+cells with lymphoid light scatter characteris-
tics increased in number following for 16 hours exposure
to HCV proteins (Figure 3a, grey bars). We previously
described these IL-10+ cells in freshly-isolated PBMC from
uninfected individuals, but found that their number fell
to almost undetectable levels following 16 hour incuba-BMC Immunology 2008, 9:28 http://www.biomedcentral.com/1471-2172/9/28
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tion in unsupplemented lymphocyte medium [22]. All of
the individuals in this study (uninfected n = 6, HIV-
infected n = 24, HIV/HCV-coinfected n = 10, HCV mono-
infected n = 3) had circulating CD36+CD61+ PBMC con-
stitutively producing IL-10 (Figure 3a, black bars). The
average percentage of PBMC producing IL-10 ex vivo
ranged from 0.37% (range 0.22–0.6%) in the HCV-
infected group to 0.75% (range 0.2–1.2%) in the unin-
fected group. Although there was a trend towards a lower
frequency of these cells in the HIV-infected, HCV-infected
and HIV/HCV-coinfected groups, there was no statistically
significant difference (Figure 3a). As previously described,
in the absence of stimulation, the percentage of PBMC
producing IL-10 in vitro decreased over time in infected
and uninfected individuals (Figure 3a, light grey bars).
The uninfected group had the highest frequency of IL-10
producing cells ex vivo (Figure 3a, black bars), however,
after for 16 hours incubation in lymphocyte medium
alone, IL-10+ cell frequency fell to similar levels in all
groups (Figure 3a, light grey bars). The mean frequencies
were slightly lower in the uninfected and HCV-infected
groups compared to the HIV-infected and HIV/HCV-coin-
fected groups (Figure 3a, light grey bars, 0.12% and 0.12%
versus 0.25%, and 0.24% respectively) but not signifi-
cantly different. The pattern of IL-10 production in
response to HCV proteins differed substantially between
groups (Figure 3a, dark grey bars). After 16 hour exposure
to HCV proteins, the average frequency of IL-10+ cells rose
to 1.63% (n = 12; range 0.1% to 6.6%) in PBMC from
HIV-infected individuals, 1.02% (n = 8; range 0.02% to
3%) in uninfected individuals, 0.27% (n = 12; range
0.01% to 1.56%) in HIV/HCV-coinfected individuals, and
0.18% (n = 3; range 0.06% to 0.26%) in HCV-infected
individuals. The number of IL-10+ cells detected by flow
cytometry following 16 hour exposure to the HCV pro-
teins was significantly higher in the HIV-infected group
compared to the HCV-infected (H = 33, p = 0.03) and
HIV/HCV coinfected (H = 15.5, p = 0.001) groups (Figure
3a). The effect of 16 hour exposure to HCV proteins on
the number of IL-10+ PBMC was quite substantial (5–10
fold increase) in HIV-infected and uninfected control
groups, while the increase in HCV-infected individuals,
Table 1: Patient characteristics.
HIV HIV/HCV Chronic HCV
Number (n) 24 10 3
Age (yrs ± SD) 41.7 ± 7.0 39.2 ± 3.85 49 ± 15
Sex (%)
M 75 80 66
F 25 20 33
HCV Genotype (%)
1 N/A 100 0
Non-1 N/A 0 0
Unknown N/A 0 100
HCV status (%)
Chronic infection (HCV RNA +) N/A 80 100
Clearance (HCV RNA -) N/A 20 0
HCV Risk Factor (%)
IVDU N/A 30 66.7
Transfusion N/A 20 33.3
Tattoo N/A 0 0
Endemic area N/A 0 0
Unknown N/A 40 0
Estimated duration of infection (yrs ± SD)1
HIV 18 ± 5.1 10 ± 2.1 N/A
HCV N/A 18 ± 3.4 24 ± 8
Antiviral therapy (%)
HIV 58 90 N/A
HCV N/A 0 0
Suppressed viral load2(%)
HIV 75 70 N/A
HCV N/A 20% Unk.
CD4+ T cell count3 (median cells/μL, interquartile range) 409, 422 608, 80 N/A
CD4+ T cell nadir4 (median cells/μL, interquartile range) 252, 296 247, 350 N/A
Abbreviations: Avg average; N/A not applicable; SD standard deviation. 1The time since clinically confirmed infection or, in the case of HCV, high 
risk activity. 2Undetectable viral load by Roche Amplicor RT-PCR test for HIV and in house PCR for HCV at the time of participation. This also 
includes those who have spontaneously cleared the virus in the case of HCV. 3Measured on the day of participation. 4Lowest documented count 
over the course of followup.BMC Immunology 2008, 9:28 http://www.biomedcentral.com/1471-2172/9/28
Page 4 of 16
(page number not for citation purposes)
Positive controls for cytokine production Figure 1
Positive controls for cytokine production. (a) IFN-γ production by CD8+ and CD8- lymphoid gated PBMC after phytohe-
magglutinin treatment. (b) IL-2 production in total PBMC after PMA/ionomycin treatment. (c) IL-10 production in CD14+ cells 
after LPS stimulation. (d) IL-12 production in CD14+ cells after LPS stimulation.
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Cytokine production following 16 hour exposure of PBMC to HCV proteins Figure 2
Cytokine production following 16 hour exposure of PBMC to HCV proteins. Freshly isolated PBMC from HIV-
infected, HCV-infected, HIV/HCV co-infected and uninfected controls were incubated for 16 hours with HCV proteins, then 
analyzed by intracellular flow cytometry for cytokine production as shown in representative plots. Selective IL-10 production 
by a small subset of CD3- PBMC with lymphoid scatter characteristics occurred in each case.
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Mean percentage of PBMC from different groups expressing IL-10 ex vivo and following 16 hour incubation with HCV proteins Figure 3
Mean percentage of PBMC from different groups expressing IL-10 ex vivo and following 16 hour incubation 
with HCV proteins. (a) The percentage of IL-10 producing cells (mean ± SE) was assessed by intracellular flow cytometry in 
freshly isolated PBMC and following 16 hour incubation with HCV proteins. Black bars represent fresh PBMC, dark grey bars 
represent PBMC incubated for 16 hours with recombinant HCV core, NS3 and NS4 and lighter grey bars represent the same 
PBMC incubated for 16 hours with β-galactosidase control protein. Statistical comparisons are made within groups using the 
Mann-Whitney U test and between groups using the Kruskal-Wallis test. (b) Representative flow plots of IL-10 production in 
PBMC from an HIV/HCV-coinfected individual after incubation of PBMC with individual HCV proteins at 2.5 μg/mL. Numbers 
represent the percentage of IL-10 positive PBMC.
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with or without HIV coinfection, was marginal (Figure
3a). If all the chronic HCV-infected individuals from the
HIV/HCV and HCV monoinfected groups are combined
into one group (n = 13), there is still a significant differ-
ence between IL-10 induction in the HIV monoinfected
group and the combined HCV chronic infection group (p
= 0.016). IL-10 induction when HCV proteins were added
together or individually was not different (Figure 3b).
There were two clear populations of IL-10 positive cells
based on the level of CD36 expression. Approximately
30% of the IL-10 positive cells had a CD36 mean channel
fluorescence (MCF) greater than 100, and the remainder
were between 10 and 100 (Figure 4a). Cells with higher
CD36 mean channel fluorescence (MCF) were more likely
to be IL-10 positive, with 100% of CD36hi cells IL-10+
versus 50–70% CD36low cells IL-10+ (Figure 4a). There is
a statistically significant difference in the mean channel
fluorescence of the CD36loIL-10lo group compared to the
CD36hiIL-10hi group (Figure 4b; Fisher's exact test, p <
0.000). This association raises the possibility of a mecha-
nistic link between high CD36 expression and IL-10 pro-
duction.
IL-10 induction is specific to HCV proteins, and 
independent of T cells and lysosomal antigen processing
To determine whether induction of IL-10 was selective for
HCV proteins, we also exposed PBMC from 5 uninfected
and 5 HIV-infected individuals to HIV p24 protein.
Unlike the HCV proteins, HIV p24 did not increase IL-10
production in PBMC relative to the β-galactosidase con-
trols (Figure 5a, black bars). Therefore, HCV core, NS3
and NS4 selectively induce IL-10 production in PBMC. To
confirm that IL-10 induction did not result from endo-
toxin contamination of the HCV antigen preparations, we
incubated PBMC from 5 uninfected and 3 HIV/HCV coin-
fected individuals with HCV proteins in the presence of
polymixin B, an endotoxin blocker. Inclusion of pol-
ymixin B in the assays had no effect on induction of IL-10
in HCV-exposed PBMC (Figure 5a, light grey bars). To test
whether antigen processing of the HCV proteins was
required for induction of IL-10, we inhibited the lyso-
somal antigen processing pathway with chloroquine in
PBMC from uninfected, HIV-infected and HIV/HCV-coin-
fected individuals exposed to HCV proteins (n = 3, n = 4,
n = 4 respectively). Chloroquine treatment did not signif-
icantly affect the IL-10+ cell frequency in PBMC from
uninfected or HIV/HCV-coinfected groups exposed to
HCV proteins (Figure 5b, grey bars with diagonal hatch).
Since the HCV proteins had the greatest effect on IL-10
induction in PBMC from HIV-infected individuals and
reduced CD4+ and total T cell numbers is an integral
aspect of HIV infection, we decided to test if the absence
of T cells affected the IL-10 response to HCV proteins.
Therefore, we depleted CD3+ T cells from the PBMC of 2
individuals in each of the HIV-infected and HIV/HCV-
coinfected groups (Figure 5b, horizontal hatch bars) and
assessed IL-10 production with and without exposure to
HCV proteins (white or grey background bars respec-
tively). The percentage of PBMC producing IL-10 constitu-
tively or in response to HCV proteins was essentially
unaffected by T cell depletion after correction for T cell
depletion.
Relationship between IL-10 induction and HCV-specific T 
cell proliferation
Since IL-10 is an immunomodulatory cytokine that sup-
presses TH1 type adaptive immunity, we investigated the
relationship between IL-10 induction by HCV proteins
and HCV-specific T cell proliferation in 10 HIV/HCV-
coinfected individuals. A positive HCV-specific prolifera-
tion response (stimulation index greater than or equal to
3) was observed in only one individual (018, Figure 6a,
black bar), who demonstrated a positive response to HCV
core but not NS3 and NS4. After 16 hour exposure to HCV
antigens, 6 of the 10 coinfected individuals tested demon-
strated an HCV protein-induced increase in the number of
IL-10+ cells (grey bars, Figure 6b). Of note, subject 018
was one of the four individuals who did not have
increased numbers of IL-10+ cells following exposure to
HCV proteins.
Discussion
In this study, we demonstrated that HCV core, NS3 and
NS4 proteins specifically and selectively induce IL-10 pro-
duction when incubated for 16 hours with PBMC. The
cells producing IL-10 in response to the HCV proteins
were identified by flow cytometry as CD14-CD36+ with
lymphoid light scatter characteristics. We previously
reported constitutive ex vivo production of IL-10 by this
PBMC subset and that this production rapidly stops in
vitro [22]. These cells do not fit into one of the major sub-
populations of circulating immune cells, but can be relia-
bly isolated from all healthy individuals tested at a
frequency of up to 1%. The ex vivo frequency of IL-10-pro-
ducing PBMC was generally equivalent in the four distinct
groups we studied, indicating that the differences seen
after 16 hour culture were caused by differential responses
to the HCV proteins. While 16 hour culture with HCV pro-
teins increased the number of IL-10-producing cells in all
groups, the frequency of IL-10+ cells was higher in PBMC
from HIV-infected individuals and uninfected controls
compared to PBMC from HIV/HCV coinfected individu-
als or HCV-infected individuals. This demonstrates a pro-
pensity for HCV-induced IL-10 production by PBMC from
uninfected individuals that is exaggerated by HIV infec-
tion and attenuated by chronic HCV infection, even in the
setting of HIV coinfection.BMC Immunology 2008, 9:28 http://www.biomedcentral.com/1471-2172/9/28
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Relationship between CD36 expression and ex vivo IL-10 production by PBMC Figure 4
Relationship between CD36 expression and ex vivo IL-10 production by PBMC. (a) Representative flow cytometry 
plot showing IL-10 production in freshly-isolated CD36+ PBMC cells with lymphoid light scatter characteristics. The percentage 
of CD36+ cells that are IL-10hi is indicated. (b) Mean channel fluorescence (MCF) for CD36 plotted against IL-10 MCF for six 
individuals. Open circles represent the CD36hi subset and dark circles represent the CD36low subset as shown in fig. 3a.
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Effect of polymyxin B, chloroquine and T cell depletion on IL-10 production by PBMC exposed to recombinant HCV proteins Figure 5
Effect of polymyxin B, chloroquine and T cell depletion on IL-10 production by PBMC exposed to recombinant 
HCV proteins. (a) Cells from uninfected individuals (n = 5) were pretreated with polymyxin B (grey bars) before incubation 
with recombinant HCV proteins to block the effects of any endotoxin contamination of the recombinant proteins. The effect 
of 16 hour exposure to recombinant HIV p24 on IL-10 induction was also assessed. (b) The mean percentage PBMC expressing 
IL-10 (± SE) from control, HIV-infected and HIV/HCV coinfected individuals was assessed after exposure to either β-galactosi-
dase (white background bars) or HCV proteins (grey background bars). Effects of treating PBMC with chloroquine (diagonal 
hatch) or depleting CD3+ T cells (horizontal hatch) are also shown for comparison with the HCV protein group (grey bars). 
Each individual was tested on at least 2 different visits.
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Anti-HCV cellular responses and IL-10 induction in HIV/HCV coinfected Individuals Figure 6
Anti-HCV cellular responses and IL-10 induction in HIV/HCV coinfected Individuals. (a) 3H-thymidine incorpora-
tion by PBMC from 10 HIV/HCV coinfected individuals incubated for 5 days with HCV core (black bar), NS3 (medium grey 
bar), NS4 (dark grey bar) or HIV p24 (light grey bar) was measured. A stimulation index of ≥3 was considered positive. Individ-
uals 18 and 150 were anti-HCV positive but HCV RNA negative at the time of testing. (b) IL-10 production in 10 HIV/HCV 
coinfected individuals after 16 hour incubation with either β-galactosidase or HCV proteins. The percentage of IL-10+ PBMC 
within the lymphoid gate is represented on the y axis. Testing was done on the same day as the proliferation data was col-
lected. Individuals 18 and 150 were anti-HCV positive but HCV RNA negative at the time of testing.
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We used recombinant HCV core, NS3 and NS4 to investi-
gate cytokine production in response to HCV proteins.
Although these three proteins have little sequence or
structural similarity and their known functions in HCV
replication are very different [23,24], we found that, col-
lectively or individually, HCV core, NS3 and NS4 proteins
induced IL-10 production in CD14-CD36+ PBMC. Others
have also reported that recombinant HCV core, NS3 and
NS4 proteins all induce IL-10 production [16,25,26].
However, in these studies, monocytes were identified as
the responding cells and, in direct contrast to our results,
there was a greater effect on monocytes from HCV-
infected individuals than on monocytes from uninfected
controls [16,27]. These studies utilized monocytes iso-
lated by overnight adherence to plastic, rather than freshly
isolated PBMC. Despite varying protocols and different
characteristics of the responding cells, the central point is
that multiple distinct HCV proteins stimulate IL-10 pro-
duction by PBMC. There are other examples of redun-
dancy in HCV protein effects as mice transgenic for
hepatic HCV structural or non-structural polyproteins
develop hepatic steatosis characteristic of chronic HCV
infection [28]. Such functional redundancy of viral pro-
teins is not unique to HCV, as three different HIV proteins
(nef, tat and vpr) have all been reported to induce IL-10
production by various PBMC subsets [29-33].
In our study, structural and non-structural HCV proteins
induced IL-10. Having both structural and non-structural
proteins with redundant immunosuppressive functions
may be important in sustaining infection. The availability
of these proteins in circulation is temporally separated,
and not concurrent. Non-structural proteins are only
expressed in actively infected cells, while the core protein
can be found in plasma at moderately high levels through-
out chronic infection [34,35]. Having multiple proteins
that induce IL-10 supports production of an immunosup-
pressive cytokine whether or not HCV replication is
upregulated or infectious virions are present.
In parallel with the redundancy in HCV protein-induced
IL-10 production, additional HCV escape mechanisms
within both the innate and adaptive immune system have
been extensively described. Subversion of the eukaryotic
anti-viral interferon-inducible system is a potent evasion
strategy employed by many viruses, and several HCV pro-
teins suppress host proteins in this system. HCV E2 inac-
tivates PKR [36], and the HCV serine protease NS3/4a
causes proteolysis of Toll-IL-1 receptor domain-contain-
ing adaptor inducing IFN-β (TRIF) [37], and inhibits
phosphorylation of IRF-3, preventing nuclear transloca-
tion and IFN-β gene activation [38]. HCV E2 has also been
associated with decreased NK cell function and HCV core
stabilizes HLA-E expression and subsequently downregu-
lates NK-mediated cytotoxicity [39-41]. HCV core, E1,
NS3, and NS4 are all associated with impaired dendritic
cell maturation, thus potentially modulating the function
of this integral link to adaptive cellular immunity
[16,27,42]. HCV core also downregulates in vitro anti-
HCV T cell responses [17,43,44]. While the exact mecha-
nism of HCV protein interaction is unclear, IL-10 inhibits
dendritic cell maturation, resulting in an immature phe-
notype similar to that seen after exposure to HCV core
[45]. Not only do HCV proteins modulate immune
responses, it is clear that more than one protein has
evolved to share similar functions. Production of IL-10 by
the cell population described in this paper may stunt den-
dritic cell maturation, and impair development of anti-
HCV cellular immunity through this pathway as well as
through a direct effect on responding T cells.
The mechanism for IL-10 induction in PBMC by HCV pro-
teins is unknown, but processing of soluble HCV antigens
through the endocytic pathway is unnecessary as blocking
antigen processing had no effect on constitutive or
induced IL-10 production. A higher percentage of cells
from HIV-infected individuals than uninfected controls
produced IL-10 in response to HCV proteins. This appears
unrelated to lower T cell function in HIV infection as
depletion of CD3+ PBMC also did not affect constitutive
or HCV-induced IL-10 production by the CD14-CD36+
PBMC.
The direct correlation between intracellular IL-10 produc-
tion and intensity of cell surface CD36 expression sup-
ports a possible connection between these molecules.
Ligands of CD36, a scavenger receptor, include oxidized
low density lipoproteins (oxLDL), thrombospondin, col-
lagen types I and IV, apoptotic cells, long chain fatty acids
and plasmodium-infected erythrocytes [46-54]. At least 2
of these ligands, thrombospondin and apoptotic cells,
have immunosuppressive or anti-inflammatory effects
[55,56]. In addition, peroxisomal proliferator associated
receptor-γ (PPAR-γ) mediated differentiation of mono-
cytes towards a less inflammatory status is accompanied
by up-regulation of CD36, which has been used to clinical
advantage in cerebral malaria [57]. While there is circum-
stantial evidence for a link between CD36 and induction
of IL-10, there has been no reported evidence of interac-
tions between HCV or any of its individual components
and CD36. HCV associates with low density lipoproteins
in circulation, and uses the LDL receptor and CD81 to
enter cells [58]. CD36 is not an HCV cellular receptor
however, recent studies suggest that HCV and the CD36
ligand oxLDL do interact [59]. HCV proteins may indi-
rectly activate IL-10 production through a CD36 related
mechanism.
IL-10 is an important immunomodulatory cytokine, and
recent experiments in the LCMV model of chronic viralBMC Immunology 2008, 9:28 http://www.biomedcentral.com/1471-2172/9/28
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infection showed that manipulating levels of IL-10 alone
was sufficient to dictate LCMV clearance or persistence
[60]. However, studies comparing plasma IL-10 levels in
HCV-infected and healthy individuals have been less
definitive, with some studies describing control levels of
serum IL-10 in chronic HCV infection, while other groups
describe a marked increase in IL-10 in chronic infection
[61-63]. This raises questions about the value of serum IL-
10 measurements, as IL-10 has important localized para-
crine effects that are not reflected by these generalized IL-
10 determinations. As well, none of these studies deter-
mine IL-10 levels during acute infection when it may be
pivotal in the establishment of chronic infection. We
demonstrated that exposure to HCV antigens in chroni-
cally infected individuals produced less IL-10 than seen in
HCV naïve individuals. Longer term exposure to HCV
antigens apparently conditions the CD36+ population of
IL-10+ cells, attenuating HCV protein specific IL-10 induc-
tion. Thus, IL-10 levels during acute infection may be
more relevant to the establishment of persistent infection
than to maintaining chronic infection.
The transience of IL-10 responses to HCV proteins may
allow emergence of cellular immune responses that are
pathological in the context of chronic HCV infection. Sev-
eral studies indicate a protective role for IL-10 in the
immunopathology of HCV infection including a clinical
trial of exogenous IL-10 administration, accumulation of
IL-10 producing CD5+ B cells in HCV-infected individuals
with mild disease and an association between high IL-10
gene polymorphism and decreased rates of HCV-related
liver fibrosis [64-67]. The diminution in IL-10 induction
seen in chronic HCV after HCV protein exposure appears
to parallel, and possibly support, insidiously progressive
liver disease.
Coinfection with HIV is an important issue in HCV infec-
tion because of its relatively high prevalence, higher HCV
virus loads in HIV/HCV coinfected individuals and
because of increased HCV-related morbidity in HIV coin-
fected individuals [68-70]. The higher level of IL-10
induction in PBMC from HIV-infected individuals may
allow the establishment of more aggressive HCV infec-
tion, with downregulation of anti-HCV responses permit-
ting increased HCV replication and higher HCV virus
loads. However, this could depend on the order of HCV
and HIV infection, with stronger anti-HCV cellular immu-
nity developing when HCV infection precedes HIV-associ-
ated CD8+  T cell activation during the asymptomatic
phase of HIV infection. Enhanced CD8+ T cell immunity
against HCV in HCV/HIV coinfected individuals is likely
to accelerate liver disease, while those who acquire HCV
following the generalized decline in cellular immunity
associated with progressive HIV infection are likely to
have especially weak HCV-specific cellular immunity.
Thus, there are 2 distinct groups of HIV/HCV coinfected
individuals with respect to HCV-specific cellular immu-
nity and its potential role in viral suppression and in the
pathogenesis of liver disease.
Chronic HCV infection mitigates IL-10 production
induced by HCV proteins. This is true in the group of three
HCV monoinfected individuals, as well as the 10 HIV/
HCV coinfected people. Though the monoinfected group
is small, the two groups with chronic HCV infection have
a total of thirteen individuals, and both have similar
results. The limited IL-10 response is even more marked
considering that the HIV monoinfected group has the
highest IL-10 induction of all groups. Therefore, the lack
of IL-10 induction in the setting of chronic infection is
likely not an artifact of the small sample size, but a real
phenomenon that can even supplant the expected HIV-
associated IL-10 induction.
Consistent with previous reports, we found that HCV spe-
cific T cell proliferation is rare in chronic HCV infection
with HIV coinfection a[71,72]. In fact, the only individual
with anti-HCV proliferative responses is also one of the
individuals with the least number of IL-10 producing cells
after HCV protein exposure.
Conclusion
We have demonstrated the presence of a novel population
of PBMC that act differentially in response to HCV pro-
teins in uninfected and HIV- or HCV-infected individuals.
This differential IL-10 response to HCV antigens is con-
sistent with the generation of an immunoregulatory envi-
ronment that promotes viral persistence in acute exposure
while allowing disease progression in the chronic state.
The behaviour of this CD36+CD14-  population offers
insight into how HCV establishes viral persistence
through decreased cellular immune responses and how
this is exacerbated by HIV infection.
Methods
Study Participants
HIV-infected and HIV/HCV-coinfected individuals were
recruited from the St. John's General Hospital Infectious
Disease Clinic, St. John's, NL, Canada. HCV-infected indi-
viduals were recruited from the Capital Health Queen
Elizabeth Hospital Hepatitis Clinic in Halifax, NS, Can-
ada. Ethics approval for this project was obtained from the
Human Investigation Committee at each institution and
all subjects provided informed written consent for blood
collection and immunological studies. Uninfected indi-
viduals were recruited from Memorial University of New-
foundland Faculty of Medicine personnel.BMC Immunology 2008, 9:28 http://www.biomedcentral.com/1471-2172/9/28
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Identification of HCV infection
HCV exposure was ascertained by testing for serum anti-
HCV antibodies using second or third generation EIA
assays from Ortho Diagnostics (Mississauga, ON). HIV
status was determined by commercially available PCR
testing by Abbott Diagnostics (Mississauga, ON).
To demonstrate the presence of HCV RNA, total nucleic
acids were extracted from plasma samples, using Nucli-
Sens® Lysis Buffer and the Nuclisens® Isolation Kit (Orga-
non Teknika, Durham, NC). Briefly, 200 μL of plasma was
added to 1 mL of lysis buffer. Silica beads were added to
bind free nucleic acids, followed by successive washes
with 70% ethanol, 95% ethanol, and acetone. Nucleic
acids were removed from the silica at 56°C with the elu-
tion buffer provided. 30 μL of eluant was frozen at -20°C
if not used immediately for cDNA synthesis.
Complementary DNA (cDNA) was produced from iso-
lated RNA using a first-strand cDNA synthesis kit (Amer-
sham Biosciences, Baie d'Urfé, Québec). 8 μL of extracted
nucleic acid was denatured at 65°C for 5 minutes and
added to a reaction mix containing random hexamer
primer, deoxyribonucleotides, and Moloney Murine
Leukemia Virus reverse transcriptase (MMLV-RT). Reac-
tions were placed at 37°C for 1 hour followed by MMLV-
RT inactivation at 95°C for 5 minutes. cDNA was stored
at -80°C until needed.
cDNA was amplified by polymerase chain reaction (PCR)
with primers specific for the highly conserved HCV 5'-
untranslated region. Primers and PCR conditions were
modified from Shindo et al. [73] as follows: forward
primer 5'-GGCGACACTCCACCATAGATC-3' and reverse
primer 5'-GGTGCACGGTCTACGAGACCT-3'. The
expected amplicon size was 324 bp. Final reactions
included 20 mM TRIS-HCl (pH 8.4), 50 mM KCl, 0.5 mM
MgCl2, 0.025 U/μL DNA polymerase (Invitrogen, Burling-
ton, Ontario), and 0.5 μM MG18 and MG321 primers
(Invitrogen, Burlington, Ontario) in 50 μL. Samples were
initially denatured at 95°C for 2 minutes, followed by
thirty cycles of amplification (95°C for one minute, 60°C
for one minute, and 72°C for one minute). PCR products
were analyzed on 2% agarose gels with ethidium bromide
visualization and stored at -20°C.
PBMC isolation and in vitro stimulation
Acid citrate dextrose (ACD) treated whole blood was
obtained by venipuncture from each individual and
PBMC were isolated by Ficoll-HyPaque Plus (GE Health
Care, Baie d'Urfé, PQ, CA) density gradient centrifugation.
Cells were washed, counted and suspended at 1 × 106/mL
in lymphocyte medium (RPMI supplemented with 10%
FCS, 10 mM HEPES, 2 mM L-glutamine, 1% penicillin/
streptomycin, and 2 × 10-5 M 2-mercaptoethanol; all from
Invitrogen, Burlington, ON, CA).
To determine the effect of HCV proteins on PBMC from
healthy and infected individuals, 1.5 × 106 freshly isolated
PBMC were incubated in lymphocyte medium at 37°C for
16 hours with 10 μg/mL Brefeldin A (Sigma Chemical
Co., St. Louis, MO, USA) and 2.5 μg/mL recombinant
HCV core, NS3, and NS4 proteins (Virogen, Watertown,
MA), 2.5 μg/mL recombinant HIV p24 from the same
source (Virogen) or 2.5 μg/mL various control proteins.
Initially, various concentrations (1, 2.5, 5, and 7.5 μg/mL)
were tested in 3 individuals to determine if there was a
dose response. All concentrations tested demonstrated
results within 0.01% of each other in each individual
(data not shown), and 2.5 μg/mL was used in subsequent
studies as it was compareable to other studies of HCV pro-
teins in human PBMC. The HCV antigens were expressed
in E. coli as β-galactosidase fusion proteins, and supplied
in a urea-based buffer, therefore, negative controls
included β-galactosidase (Calbiochem, La Jolla, CA) in
the same buffer as the viral antigens. Polymixin B sulfate
(PMB; Sigma) was added at 100 μg/mL to block any endo-
toxin-induced cytokine production as described previ-
ously[74]. For some experiments, the lysosomal antigen
processing pathway inhibitor chloroquine (Sigma) was
added at 50 μM to PBMC 30 minutes before addition of
HCV antigens to investigate whether antigen processing
was involved in IL-10 induction. Cytokine production
was assessed by intracellular flow cytometry.
T cell depletion
For some experiments, CD3+ T cells were removed from
fresh PBMC by depletion with magnetic beads. Ten mil-
lion fresh PBMC were washed and resuspended in cold
depletion buffer (PBS supplemented with 5 mM EDTA
and 0.5% BSA) at 3 × 106/mL, and a 10:1 bead-to-target
cell ratio with mouse anti-human CD3-coated magnetic
beads (Dynal ASA, Lake Success, NY). Cells and beads
were rotated together for 45 minutes at 4°C, and bead
bound CD3+ cells were removed using a magnet. Deple-
tion efficiency was >97% as determined by flow cytome-
try. The remaining cells were resuspended in lymphocyte
medium and exposed to HCV and HIV proteins as
described above.
Flow cytometry
Surface staining
PBMC subpopulations were phenotyped by surface and
intracellular flow cytometry using the following antibod-
ies: CD3-phycoerythrin (PE; Clone UCHT1, DakoCyto-
mation, Mississauga, ON), CD4-fluorescein
isothiocyanate (FITC; Clone RPA-T4, BD Pharmingen,
San Diego, CA), CD8-peridinin chlorophyll (PerCP;
Clone RPA-T8, BD Pharmingen), CD14-FITC or CD14-PEBMC Immunology 2008, 9:28 http://www.biomedcentral.com/1471-2172/9/28
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(Clone M5E2, BD Pharmingen), CD36-PE (Clone CB38,
BD Pharmingen), CD19-FITC (Clone HIB19, BD
Pharmingen), CD56-FITC (Clone HA58, BD Pharmin-
gen) and CD61-PerCP (clone VI-PL2, BD Pharmingen).
To each tube, IL-10 and CD36 were added, along with one
other surface marker for each major cell type (e.g. CD36,
IL-10, and CD3). Through this strategy, 3 color flow
cytometry was used to identify the cell population of
interest. All steps were performed at 4°C, and incubations
were carried out in the dark to prevent fluorochrome pho-
tobleaching. Approximately 5 × 105 PBMC were washed
with flow cytometry buffer (PBS supplemented with 0.1%
bovine serum albumin (BSA), 5 mM EDTA and 0.02%
sodium azide, all from Sigma), resuspended in 600 μL
and incubated for 20 minutes with 0.5 μg antibody
against surface antigens or appropriate isotype controls.
Cells were washed, fixed with 0.5 mL 1% paraformalde-
hyde (Sigma) for 20 minutes, resuspended in 250 μL of
1% paraformaldehyde, and stored at 4°C until analysis
on a FACScan flow cytometer (Becton Deckinson). Cel-
lQuest Pro™ and WinMDI™ were used for data analysis.
Intracellular staining
Cells were stained as above for surface antigens with an
additional permeabilization step after fixation. Cells were
incubated with either 0.5 mL 0.2% saponin (Sigma) in
PBS or DAKO permeabilization reagent and anti-IL-10
FITC (clone JES9D7 Caltag, Burlingame, CA), anti-IFN-γ
FITC, (clone B27, Caltag), anti-IL-2 FITC, (clone MQ1-
17H12 Caltag) anti-IL-12 FITC (clone C8.6 Caltag) anti-
bodies or appropriate isotype controls for 20 minutes at
4°C in the dark. After washing with 3 mL flow buffer, cells
were resuspended in 1% paraformaldehyde until analysis.
Total PBMC were incubated for 16 hours with either 5 μg/
mL phytohemagglutinin, 10 nM phorbol 12-myristate 13-
acetate (PMA)/100 nM ionomycin, or 200 ng/mL lipopol-
ysaccaride to provide positive controls for IFN-γ, IL-2, IL-
10, and IL-12 production, respectively. Brefeldin A was
added one hour after the various stimulants. Lymphoid
cells were gated and stained for CD8 and IFN-γ produc-
tion, total PBMC for IL-2 production, and monocytes
were gated for IL-12 and IL-10 production.
Proliferation assays
Cellular immune responses were measured by standard 5
day thymidine incorporation assay. PBMC were washed
twice with proliferation medium (lymphocyte medium
with 10% human AB serum (Atlanta Biologicals, lot
number M0102) substituted for FBS) and 1 × 105 cells/
well were incubated in triplicate with either plain
medium, 5 μg/mL phytohemagglutinin (ICN Biomedicals
Inc., Costa Mesa, CA), 2.5 μg/mL Candida albicans (Greer
Laboratories Inc., Lenoir, NC), or 2 μg/mL HCV core, NS3,
NS4 or HIV p24 (all Virogen) for 5 days. One μCi of triti-
ated (3H)-thymidine (Perkin Elmer Life Sciences, Boston,
MA) was added to each well on day 4, and the assay was
harvested onto glass fiber mats 18 hours later using a
semi-automated harvester (Tomtec Harvester 96 Mach M
III, Hamden, CT). Incorporated 3H-thymidine was meas-
ured by a 96 well scintillation counter (TopCount, Pack-
ard, Meriden, CT). Stimulation indices were calculated as
follows:
Statistical Analyses
All statistical analyses were performed using SPSS version
9 (SPSS Inc., Chicago, IL). In figure 2, the group sizes were
small and unequal. Therefore, nonparametric tests were
used to compare means. Within a group, the Mann-Whit-
ney U test was used, while the Kruskal-Wallis test was used
to test for differences between groups, as there were
greater than 3 groups. Neither test depends on the data
distribution for calculation, and the Kruskal-Wallis for
multiple comparisons adjusts the alpha value to avoid
inflation of type I error. In figure 3, the Fisher's exact test
was used to compare the categorical data. All graphs indi-
cate mean values and error bars represent standard error
of the mean.
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